LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,000 | – | 2,079 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 5,036,720 | $14,354,000 | 4.77% |
| BROADWOOD CAPITAL INC | 34,005,379 | $96,915,000 | 4.33% |
| Prescott General Partners LLC | 1,851,851 | $5,278,000 | 0.17% |
| Raffles Associates | 43,590 | $124,000 | 0.10% |
| Laidlaw Wealth Management LLC | 123,730 | $353,000 | 0.09% |
| DCF Advisers, LLC | 74,500 | $212,000 | 0.08% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $128,000 | 0.07% |
| Strategic Wealth Investment Group, LLC | 64,232 | $183,000 | 0.06% |
| Paradigm, Strategies in Wealth Management, LLC | 19,775 | $56,000 | 0.05% |
| Fort Sheridan Advisors LLC | 47,931 | $137,000 | 0.05% |